Laval, November 3, 2015 – It was in the presence of Mr. Jacques Daoust, Minister of the Economy, Innovation, and Exports, Ms. Francine Charbonneau, Minister responsible for Seniors, Minister of Families, Minister responsible for Anti-Bullying, Minister responsible for the Laval region, and MNA for Mille-Îles, Mr. Marc Demers, Mayor of the City of Laval, and Mr. Paul Lirette, President, GlaxoSmithKline Pharma Canada, that Mr. Max Fehlmann, President and CEO of the NEOMED Institute, officially marked the opening of the biologics and vaccines division of the NEOMED Institute in Laval. The inaugural ceremony took place yesterday, Monday, November 2nd and was attended by over 160 members of the Quebec life sciences community and dignitaries of the City of Laval.
This inauguration follows the signing of a $47 million partnership with GlaxoSmithKline and the success of the NEOMED Institute’s innovative business model via its first division, dedicated to developing small molecule therapeutics and located at Technoparc Montréal’s Saint-Laurent Campus. The transformation of the Laval research facility into a multi-tenant centre to unite small and medium enterprises specialized in the development of biologics and vaccines has already begun. The site is now home to four companies:
During the ceremony, Mr. Max Fehlmann commended the dynamism and capacity for innovation of the Quebec life sciences industry and reinforced the importance of partnerships and collaborations in the field of pharmaceutical research. Across its two sites, the NEOMED Institute now has 26 independent companies employing 293 people.
ABOUT THE NEOMED INSTITUTE
The NEOMED Institute is a not-for-profit organization whose mission is to create a bridge between basic research and the commercialization of new drugs by providing industrial expertise in drug discovery and development, combined with funding and a favourable ecosystem, to transform innovations into solid therapeutic solutions. NEOMED drives drug discovery activities up to the stage of human proof of concept. The NEOMED Institute has two fully integrated research and development facilities: one in Technoparc Montréal’s Saint-Laurent Campus, specializing in small molecule therapeutics, and the other facility, specializing in the development of biologics and vaccines, in Laval. Both facilities function as open-access drug discovery hubs housing independent commercial businesses and providing a dynamic environment that stimulates collaboration, innovation, and creativity.
The NEOMED Institute is jointly funded by the pharmaceutical industry, the Ministère de l’Économie, de l’Innovation et des Exportations du Québec, and the Networks of Centres of Excellence (NCE) of Canada.
For more information, please visit our website: www.neomed.ca.
For more information, please contact:
Montreal, Quebec H4S 1Z9
514-367-1212 x 209
Pictured, from left to right, are:
Ms. Christiane Yoakim, City Councillor for Val-des-Arbres, Laval; Mr. Marc Demers, Mayor of the City of Laval; Mr. Jean Habel, MNA for Sainte-Rose; Mr. Paul Lirette, President, GlaxoSmithKline Pharma Canada; Mr. Saul Polo, MNA for Laval-des-Rapides; Ms. Francine Charbonneau, Minister responsible for Seniors, Minister of Families, Minister responsible for Anti-Bullying, Minister responsible for the Laval region, and MNA for Mille-Îles; Mr. Max Fehlmann, President and CEO of NEOMED Institute; and Mr. Jacques Daoust, Minister of the Economy, Innovation, and Exports